COMPASS Pathways (CMPS) Competitors $4.61 +0.30 (+6.96%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$4.59 -0.02 (-0.43%) As of 08/22/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPS vs. IMCR, AUPH, CDTX, WVE, JANX, SDGR, EWTX, HROW, ARDX, and ETNBShould you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Immunocore (IMCR), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), WAVE Life Sciences (WVE), Janux Therapeutics (JANX), Schrodinger (SDGR), Edgewise Therapeutics (EWTX), Harrow (HROW), Ardelyx (ARDX), and 89BIO (ETNB). These companies are all part of the "pharmaceutical products" industry. COMPASS Pathways vs. Its Competitors Immunocore Aurinia Pharmaceuticals Cidara Therapeutics WAVE Life Sciences Janux Therapeutics Schrodinger Edgewise Therapeutics Harrow Ardelyx 89BIO COMPASS Pathways (NASDAQ:CMPS) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership. Is CMPS or IMCR more profitable? COMPASS Pathways has a net margin of 0.00% compared to Immunocore's net margin of -5.70%. Immunocore's return on equity of -5.40% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets COMPASS PathwaysN/A -87.89% -57.77% Immunocore -5.70%-5.40%-1.93% Which has more risk & volatility, CMPS or IMCR? COMPASS Pathways has a beta of 2.17, meaning that its share price is 117% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Do insiders & institutionals hold more shares of CMPS or IMCR? 46.2% of COMPASS Pathways shares are owned by institutional investors. Comparatively, 84.5% of Immunocore shares are owned by institutional investors. 3.9% of COMPASS Pathways shares are owned by insiders. Comparatively, 10.4% of Immunocore shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable earnings and valuation, CMPS or IMCR? Immunocore has higher revenue and earnings than COMPASS Pathways. Immunocore is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOMPASS PathwaysN/AN/A-$155.12M-$1.84-2.51Immunocore$356.15M4.66-$51.09M-$0.40-82.33 Does the media prefer CMPS or IMCR? In the previous week, COMPASS Pathways and COMPASS Pathways both had 2 articles in the media. Immunocore's average media sentiment score of 1.14 beat COMPASS Pathways' score of 0.90 indicating that Immunocore is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment COMPASS Pathways 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Immunocore 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend CMPS or IMCR? COMPASS Pathways currently has a consensus price target of $16.29, suggesting a potential upside of 253.27%. Immunocore has a consensus price target of $58.00, suggesting a potential upside of 76.13%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more favorable than Immunocore.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score COMPASS Pathways 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Immunocore 1 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryImmunocore beats COMPASS Pathways on 8 of the 13 factors compared between the two stocks. Get COMPASS Pathways News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPS vs. The Competition Export to ExcelMetricCOMPASS PathwaysMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$413.51M$7.71B$5.75B$9.62BDividend YieldN/A2.71%4.40%4.10%P/E Ratio-2.5178.4731.3026.05Price / SalesN/A45.29432.98193.75Price / CashN/A24.6737.7358.48Price / Book2.7324.799.536.61Net Income-$155.12M$243.33M$3.26B$265.65M7 Day Performance6.71%1.08%2.13%2.02%1 Month Performance-0.22%-0.65%2.80%-0.31%1 Year Performance-35.88%10.34%30.68%19.06% COMPASS Pathways Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPSCOMPASS Pathways2.5555 of 5 stars$4.61+7.0%$16.29+253.3%-33.7%$413.51MN/A-2.51120Positive NewsIMCRImmunocore1.7879 of 5 stars$32.31-1.7%$58.00+79.5%-7.5%$1.63B$310.20M-80.78320Positive NewsAUPHAurinia Pharmaceuticals2.6434 of 5 stars$12.22-0.4%$12.00-1.8%+84.5%$1.61B$235.13M28.42300Positive NewsCDTXCidara Therapeutics3.5877 of 5 stars$63.24-3.0%$64.14+1.4%+412.1%$1.60B$1.27M-5.6890Positive NewsWVEWAVE Life Sciences4.7491 of 5 stars$9.74-0.2%$20.27+108.1%+83.9%$1.55B$108.30M-10.82240Positive NewsJANXJanux Therapeutics2.0629 of 5 stars$25.53+1.7%$91.89+259.9%-45.0%$1.53B$10.59M-14.1830News CoverageSDGRSchrodinger3.0962 of 5 stars$20.05+3.5%$27.83+38.8%+4.3%$1.48B$207.54M-8.08790EWTXEdgewise Therapeutics2.5706 of 5 stars$14.00-1.1%$41.60+197.1%-24.2%$1.47BN/A-9.0360Analyst ForecastHROWHarrow3.6368 of 5 stars$38.32-1.3%$64.67+68.8%-5.3%$1.42B$199.61M-153.28180Analyst RevisionARDXArdelyx4.3251 of 5 stars$5.81-2.7%$11.50+97.9%+1.0%$1.40B$333.61M-25.2690Positive NewsETNB89BIO2.0016 of 5 stars$9.44+2.3%$26.29+178.5%+11.3%$1.40BN/A-2.6140 Related Companies and Tools Related Companies IMCR Competitors AUPH Competitors CDTX Competitors WVE Competitors JANX Competitors SDGR Competitors EWTX Competitors HROW Competitors ARDX Competitors ETNB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPS) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share COMPASS Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access